The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia

• Published in: European neuropsychopharmacology 2017-02, Vol.27 (2), p.180-191
• Main Authors: Prades, Roger, Munarriz-Cuezva, Eva, Urigüen, Leyre, Gil-Pisa, Itziar, Gómez, Lídia, Mendieta, Laura, Royo, Soledad, Giralt, Ernest, Tarragó, Teresa, Meana, J. Javier
• Format: Article
• Language: English
• Subjects: Animal model; Animals; Cell Line, Tumor; Cognition; Cognition - drug effects; Cognition - physiology; Cognition Disorders - drug therapy; Cognition Disorders - enzymology; Cognition Disorders - etiology; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Internal Medicine; Male; Maze Learning - drug effects; Maze Learning - physiology; Mice, Inbred C57BL; Motor Activity - drug effects; Motor Activity - physiology; Peptidomimetic; Poly I-C; Prepulse Inhibition - drug effects; Prepulse Inhibition - physiology; Proline - analogs & derivatives; Proline - chemistry; Proline - pharmacokinetics; Proline - pharmacology; Proline - toxicity; Prolyl oligopeptidase; Psychiatry; Psychotropic Drugs - chemistry; Psychotropic Drugs - pharmacokinetics; Psychotropic Drugs - pharmacology; Psychotropic Drugs - toxicity; Recognition (Psychology) - drug effects; Recognition (Psychology) - physiology; Schizophrenia; Schizophrenia - complications; Schizophrenia - drug therapy; Schizophrenia - enzymology; Schizophrenic Psychology; Serine Endopeptidases - metabolism; Serine Proteinase Inhibitors - chemistry; Serine Proteinase Inhibitors - pharmacokinetics; Serine Proteinase Inhibitors - pharmacology; Serine Proteinase Inhibitors - toxicity
• ISSN: 0924-977X; 1873-7862
• DOI: 10.1016/j.euroneuro.2016.11.016

Abstract Cognitive deficits are considered a key feature of schizophrenia, and they usually precede the onset of the illness and continue after psychotic symptoms appear. Current antipsychotic drugs have little or no effect on the cognitive deficits of this disorder. Prolyl oligopeptidase (POP) is an 81-kDa monomeric serine protease that is expressed in brain and other tissues. POP inhibitors have shown neuroprotective, anti-amnesic and cognition-enhancing properties. Here we studied the potential of IPR19, a new POP inhibitor, for the treatment of the cognitive symptoms related to schizophrenia. The efficacy of the inhibitor was evaluated in mouse models based on subchronic phencyclidine and acute dizocilpine administration, and in adult offspring from mothers with immune reaction induced by polyinosinic:polycytidylic acid administration during pregnancy. Acute IPR19 administration (5 mg/kg, i.p.) reversed the cognitive performance deficits of the three mouse models in the novel object recognition test, T-maze, and eight-arm radial maze. The compound also ameliorates deficits of the prepulse inhibition response. The in vitro inhibitory efficacy and selectivity, brain penetration and exposure time after injection of IPR19 were also addressed. Our results indicate that the inhibition of POP using IPR19 may offer a promising strategy to develop drugs to ameliorate the cognitive deficits of schizophrenia.